Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines

References

• Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–76. doi:10.1016/J.IJSU.2020.02.034
   PubMed Web of Science ®Google Scholar
• Rauf A, Abu-Izneid T, Olatunde A, et al. COVID-19 Pandemic: epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health. 2020;17(21):1–32. doi:10.3390/IJERPH17218155
   Web of Science ®Google Scholar
• Alsagaby SA, Aljouie A, Alshammari TH, et al. Haematological and radiological-based prognostic markers of COVID-19. J Infect Public Health. 2021;14(11):1650–1657. doi:10.1016/J.JIPH.2021.09.021
   Web of Science ®Google Scholar
• WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Available from: https://covid19.who.int/. Accessed November 10, 2021.
   Google Scholar
• Forni G, Mantovani A, Forni G, et al. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–639. doi:10.1038/S41418-020-00720-9
   PubMed Web of Science ®Google Scholar
• Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(20):749–752. doi:10.15585/MMWR.MM7020E1
   Web of Science ®Google Scholar
• Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922–1924. doi:10.15585/MMWR.MM6950E2
   PubMed Web of Science ®Google Scholar
• Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA. 2021;325(8):780–781. doi:10.1001/JAMA.2021.0600
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMOA2034577
   PubMed Web of Science ®Google Scholar
• Covid CD, Team R. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. doi:10.15585/MMWR.MM7002E1
   Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1
   PubMed Web of Science ®Google Scholar
• Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021:373. doi:10.1136/BMJ.N1114
   Web of Science ®Google Scholar
• Wise J. Covid-19: european countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699. doi:10.1136/BMJ.N699
   PubMed Web of Science ®Google Scholar
• Lundstrom K, Barh D, Uhal BD, et al. COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street? Biomolecules. 2021;11(7):1020. doi:10.3390/BIOM11071020
   Web of Science ®Google Scholar
• Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021;71:111–116. doi:10.1016/J.COI.2021.07.003
   PubMed Web of Science ®Google Scholar
• Yang L, Liu S, Liu J, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5:1. doi:10.1038/S41392-020-00243-2
   PubMed Web of Science ®Google Scholar
• Boudjelal M, Almajed F, Salman AM, et al. COVID-19 vaccines: global challenges and prospects forum recommendations. Int J Infectious Dis. 2021;105:448–451. doi:10.1016/J.IJID.2021.02.093
   PubMed Web of Science ®Google Scholar
• Bosaeed M, Balkhy HH, Almaziad S, et al. Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, Phase 1b trial. Lancet Microbe. 2021. doi:10.1016/S2666-5247(21)00193-2
   Google Scholar
• Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021. doi:10.1056/NEJMOA2114583
   Web of Science ®Google Scholar
• Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health Europe. 2021;10:100208. doi:10.1016/J.LANEPE.2021.100208
   PubMedGoogle Scholar
• Mahallawi WH, Fakher MH, Alsarani MA, Aljohani RH, Al-Mutabgani SA, Ibrahim NA. A Single Dose of SARS-CoV-2 Vaccine Primes a Strong Humoral Immune Response in COVID-19-Recovered Patients. Viral Immunol. 2021. doi:10.1089/VIM.2021.0108/ASSET/IMAGES/LARGE/VIM.2021.0108_FIGURE6.JPEG
   Web of Science ®Google Scholar
• Garg J, Singh V, Pandey P, et al. Evaluation of sample pooling for diagnosis of COVID-19 by real time-PCR: a resource-saving combat strategy. J Med Virol. 2021;93(3):1526–1531. doi:10.1002/JMV.26475
   PubMed Web of Science ®Google Scholar
• Interim Guidance for Use of Pooling Procedures in SARS-CoV-2 Diagnostic and Screening Testing | CDC. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html. Accessed November 10, 2021.
   Google Scholar
• Alharbi NK, Alghnam S, Algaissi A, et al. Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia. J Infect Public Health. 2021;14(7):832–838. doi:10.1016/J.JIPH.2021.04.006
   Web of Science ®Google Scholar
• Chappell KJ, Mordant FL, Li Z, et al. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2021;21(10):1383–1394. doi:10.1016/S1473-3099(21
   Web of Science ®Google Scholar
• Amanat F, White KM, Miorin L, et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020;58(1):e108. doi:10.1002/cpmc.108
   PubMedGoogle Scholar
• Algaissi A, Hashem AM. Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay. Methods Mol Biol. 2020;2099:107–116. doi:10.1007/978-1-0716-0211-9_9
   PubMedGoogle Scholar
• Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–2261. doi:10.1056/NEJMC2103916
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761–1773. doi:10.1056/NEJMOA2110345
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi:10.1038/S41591-021-01377-8
   PubMed Web of Science ®Google Scholar
• Wheeler SE. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr. 2021;9(1). doi:10.1128/SPECTRUM.00341-21
   Web of Science ®Google Scholar
• Baumgarth N, Nikolich-žugich J, Lee FEH, Bhattacharya D. Antibody Responses to SARS-CoV-2: let’s Stick to Known Knowns. J Immunol. 2020;205(9):2342–2350. doi:10.4049/JIMMUNOL.2000839
   PubMed Web of Science ®Google Scholar
• Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma Cells. Front Immunol. 2019;10. doi:10.3389/FIMMU.2019.00721
   Web of Science ®Google Scholar
• Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54(2):205–210. doi:10.1016/J.IMMUNI.2021.01.014
   Web of Science ®Google Scholar
• Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533–1535. doi:10.1001/JAMA.2021.15125
   PubMed Web of Science ®Google Scholar
• Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595(7867):426–431. doi:10.1038/S41586-021-03696-9
   PubMed Web of Science ®Google Scholar
• Angyal A, Longet S, Moore S, et al. T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: a Multicentre, Prospective, Observational Cohort Study. SSRN Electronic J. 2021. doi:10.2139/SSRN.3812375
   Google Scholar
• Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022;7(1):14. doi:10.1038/s41541-022-00432-w
   Web of Science ®Google Scholar
• Payne RP, Longet S, Austin JA, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184(23):5699–5714.e11. doi:10.1016/j.cell.2021.10.011
   PubMed Web of Science ®Google Scholar
• Amirthalingam G, Bernal JL, Andrews NJ, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021;12(1):7217. doi:10.1038/s41467-021-27410-5
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. doi:10.1016/S0140-6736(21
   PubMed Web of Science ®Google Scholar
• Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet. 2021;398(10304):981–990. doi:10.1016/S0140-6736(21)01699-8
   PubMed Web of Science ®Google Scholar
• Wei J, Pouwels KB, Stoesser N, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022. doi:10.1038/s41591-022-01721-6
   Web of Science ®Google Scholar
• Müller M, Volzke J, Subin B, et al. Single-Dose SARS-CoV-2 Vaccination With BNT162b2 and AZD1222 Induce Disparate Th1 Responses and IgA Production. medRxiv. 2021;2021:21263726. doi:10.1101/2021.09.17.21263726
   Google Scholar
• Müller M, Volzke J, Subin B, et al. Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production. BMC Med. 2022;20(1):29. doi:10.1186/s12916-022-02240-4
   Web of Science ®Google Scholar
• Zurac S, Nichita L, Mateescu B, et al. COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers. Mol Med Rep. 2021;24:2. doi:10.3892/mmr.2021.12217
   Web of Science ®Google Scholar
• Madhumita Shrotri A, Fragaszy E, Geismar C, et al. Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch). medRxiv. 2021;2021. doi:10.1101/2021.05.12.21257102
   Google Scholar
• Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(14):1372–1374. doi:10.1056/NEJMC2101667
   PubMed Web of Science ®Google Scholar
• Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021;325(14):1467–1469. doi:10.1001/JAMA.2021.3341
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984. doi:10.1038/S41591-021-01325-6
   PubMed Web of Science ®Google Scholar
• Mazzoni A. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021;131(12). doi:10.1172/JCI149150
   Web of Science ®Google Scholar
• Gobbi F, Buonfrate D, Moro L, et al. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021;13:3. doi:10.3390/V13030422
   Web of Science ®Google Scholar
• Parry H, Bruton R, Tut G, et al. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. Lancet Healthy Longev. 2021;2(9):e554–e560. doi:10.1016/S2666-7568(21)00169-0
   Google Scholar
• Bernal JL, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373. doi:10.1136/BMJ.N1088
   Web of Science ®Google Scholar
• Simon B, Rubey H, Treipl A, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrol Dialysis Transplanta. 2021;36(9):1709–1716. doi:10.1093/NDT/GFAB179
   Web of Science ®Google Scholar
• Dispinseri S, Lampasona V, Secchi M, et al. Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. J Clin Endocrinol Metab. 2021;106(5):1472–1481. doi:10.1210/CLINEM/DGAB055
   Web of Science ®Google Scholar